Cargando…
Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response
OBJECTIVES: PD-L1 expression on tumour cells can guide the use of anti-PD-1/PD-L1 immune modulators to treat patients with non-small cell lung cancer (NSCLC). Heterogeneity of PD-L1 expression both within and between tumour sites is a well-documented phenomenon that compromises its predictive power....
Autores principales: | Haragan, Alexander, Field, John K., Davies, Michael P.A., Escriu, Carles, Gruver, Aaron, Gosney, John R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Scientific Publishers
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6658831/ https://www.ncbi.nlm.nih.gov/pubmed/31320000 http://dx.doi.org/10.1016/j.lungcan.2019.06.005 |
Ejemplares similares
-
Accelerated instability testing reveals quantitative mass spectrometry overcomes specimen storage limitations associated with PD-L1 immunohistochemistry
por: Haragan, Alexander, et al.
Publicado: (2020) -
Reliability of PD-L1 assays using small tissue samples compared with surgical specimens
por: Kim, Insu, et al.
Publicado: (2019) -
Treatment beyond four cycles of first line Platinum and Etoposide chemotherapy in real-life patients with stage IV Small Cell Lung Cancer: a retrospective study of the Merseyside and Cheshire Cancer network
por: Sallam, Mostafa, et al.
Publicado: (2019) -
Analysis of Immune Checkpoint Drug Targets and Tumor Proteotypes in Non-Small Cell Lung Cancer
por: Liebler, Daniel C., et al.
Publicado: (2020) -
Aurora B expression modulates paclitaxel response in non-small cell lung
cancer
por: Al-Khafaji, Ahmed SK, et al.
Publicado: (2017)